Ultra-high resolution optical coherence tomography for monitoring tear meniscus volume in dry eye after topical cyclosporine treatment

Jianhua Wang¹
Lele Cui¹
Meixiao Shen¹
Victor L Perez¹
Michael R Wang²

¹Bascom Palmer Eye Institute, University of Miami Leonard M Miller School of Medicine, ²Electrical and Computer Engineering, University of Miami, Miami, FL, USA

Purpose: This study was designed to determine the ability of ultra-high-resolution optical coherence tomography (UHR-OCT) to monitor tear meniscus volume after dry eye treatment with Restasis® (0.05% cyclosporine).

Methods: UHR-OCT was used to image the upper and lower tear menisci (height and volume) in 14 consecutive dry eye patients at baseline. The treatment group was initiated on daily Restasis and measurements were repeated at 1 and 2 months while on treatment. All measurements were performed immediately after a blink.

Results: The baseline tear meniscus volumes were $0.40 \pm 0.19 \mu L$ (upper) and $0.43 \pm 0.18 \mu L$ (lower). In the treatment group, tear meniscus heights showed significant increases of both upper (post-hoc test with Bonferroni correction: $P = 0.003$) and lower ($P = 0.0003$) tear menisci, after 1 month on Restasis. The tear meniscus volumes in the treatment group after 1 month of Restasis showed significant increases of both upper ($P = 0.007$) and lower ($P = 0.007$) tear menisci. At 2 months, the increase of the tear meniscus was still evident in all measured variables compared with baseline ($P < 0.05$).

Conclusion: UHR-OCT offers a promising tool for monitoring dry eye treatment. With this method, a measurable increase in tear meniscus volume was evident after 1 month of treatment with Restasis in dry eye patients.

Keywords: tear menisci, UHR-OCT, tear dynamics, dry eye, Restasis®

Introduction

Adequate tear volume on the ocular surface is essential for maintaining ocular surface integrity and comfort. The majority of tear volume is in the tear menisci, including both the upper and the lower tear meniscus.¹ Tear meniscus volume has been found to be significantly lower in dry eye patients. Recently, optical coherence tomography (OCT) has been utilized to quantify tear meniscus volume and to diagnose dry eye.²,³ In addition, OCT technology has been used to evaluate tear dynamics after instillation of artificial tears⁴ and occlusion of the punctum.⁵

The topical cyclosporine ophthalmic solution (Restasis®, Allergan, Irvine, CA), is a US Food and Drug Administration-approved treatment for dry eye disease.⁶ Its mechanism reduces inflammation of the ocular surface, resulting in increased tear production.⁶ Increased tear production, as measured by Schirmer’s test (an invasive method), has been found in dry eye patients treated with topical cyclosporine.⁷ A noninvasive method may be useful in determining the increase in tear volume after treatment and can be used in routine clinic situations for evaluating the efficacy of treatment in individual patients. Using high-resolution OCT, we have previously
demonstrated that the use of artificial tears does not lead to sustained increases in tear volume as blinking returns tear volume to baseline within 30 minutes of artificial tear instillation.\textsuperscript{4,8} Our previous work has also demonstrated that OCT is capable of monitoring upper and lower tear menisci in both symptomatic and non-symptomatic patients with dry eye.\textsuperscript{2,5,10} To the best of our knowledge, tear meniscus volume after Restasis treatment has not been examined using ultra-high-resolution OCT (UHR-OCT). This study was designed to determine the tear meniscus volume after dry eye treatment with Restasis (0.05\%) using the novel UHR-OCT.

**Subjects and methods**

This prospective study was approved by the research boards of the University of Miami. Fourteen consecutive, clinically diagnosed aqueous tear deficiency (ATD) dry eye patients (seven women and seven men; mean age ± standard deviation: 45.7 ± 21.1 years) were recruited for the Restasis treatment group. Key inclusion criteria included dry eye symptoms and signs (Schirmer’s test: ≤5 mm, staining ≥ 1, or tear break-up time [TBUT] ≤ 10 seconds). The Schirmer’s test with anesthesia was performed. A test strip was placed inside the conjunctival sac and the patient closed their eyes for 5 minutes. The length of moisture on the test strip was measured in millimeters. After the instillation of fluorescein, TBUT was recorded through a standard slit-lamp using cobalt blue light and a yellow filter. The time for dry spots to appear after blinking was recorded. Three tests were averaged. Staining grading was done through a standard slit-lamp when TBUT was evaluated. The Center for Contact Lens Research Unit grading scale was used for ranking the scores. Patients who were treated with Restasis were excluded. Patients in the treatment group were treated with Restasis twice a day in both eyes. No additional artificial tears were used in either group.

An ultra-high-resolution (3 \(\mu\)m) spectral domain UHR-OCT has been described elsewhere.\textsuperscript{11,12} A three-module, superluminescent diode light source (BrodlighterT-840-HP; Superlum, Carrigtwohill, Ireland) with a center wavelength of 840 nm and a full width at half maximum bandwidth of 100 nm was used. The sample light was delivered to a light delivery system with a telecentric design, which consisted of an X-Y galvanometer scanner (Model 6215 Moving Magnet Closed Loop Galvanometer; Cambridge Technology, Lexington, MA). The scanner was mounted with a standard slit-lamp microscope. The power of the incident light delivered into the anterior segment was lowered to 750 \(\mu\)W to ensure the safety of the eye. The scan width was set to 12 mm, with a depth of 3 mm. The scan speed of the system was set to 24,000 A-scans per second. An external fixation target was used and a video system was applied to align the eye for imaging. The upper and lower tear menisci (height, cross-sectional area, volume) were imaged at the vertical meridian across the apex. After the eye was imaged at baseline, all patients were initiated on twice-daily Restasis treatment. OCT measurements were repeated at 1 and 2 months while on treatment. The patient was instructed not to instill Restasis on the study day, and all images were taken immediately after a blink.

The lab settings of the exam room were similar to previous studies.\textsuperscript{1,4} Briefly, the temperature (15°C–25°C) and humidity (30%–50%) in a small consulting room were controlled by central air conditioning and two humidifiers. Ambient light was used while imaging each subject. The images (Figure 1) showing both upper and lower tear menisci were processed with custom software, to yield upper and lower tear menisci heights and cross-sectional areas. Tear volumes in upper and lower tear menisci were calculated as described in previous studies.\textsuperscript{1,2} The volume was calculated as the product of meniscus cross-sectional area and eyelid length, obtained from a digital photograph of the eye taken during the baseline visit. As upper and lower lids are also curved in the third dimension, a multiplication factor of 1.294 was used, as suggested by Tiffany et al.\textsuperscript{13}

Data analysis was conducted using Statistica software (v. 10; StatSoft, Tulsa, OK). Two-way repeated-measures analysis of variance was used for overall effects and post-hoc paired \(t\)-tests, with Bonferroni correction were used to determine whether there were pair-wise differences (\(P < 0.05\)) after the dry eye treatment.

**Results**

In the treatment group (Table 1 and Figure 2), tear meniscus heights showed significant increases of both upper (post-hoc test with Bonferroni correction: \(P = 0.003\)) and lower (\(P = 0.0003\)) tear menisci after 1 month on Restasis. The tear meniscus volumes in the treatment group after 1 month of Restasis showed significant increases of both upper (\(P = 0.007\)) and lower (\(P = 0.007\)) tear menisci. At 2 months, the increase of the tear meniscus was still evident in all measured variables compared with baseline (\(P < 0.05\)) (Figures 3 and 4). The baseline tear meniscus volumes were \(0.40 ± 0.19 \mu\)L (upper) and \(0.43 ± 0.18 \mu\)L (lower) (Figure 4). At 2 months, the upper and lower tear meniscus volumes were \(0.56 ± 0.26 \mu\)L and \(0.69 ± 0.37 \mu\)L, respectively (Figure 4).
Many clinical tests have been used to evaluate the tear system and, ultimately, to diagnose dry eye. These tests include tear break-up time for tear stability, Schirmer’s test for tear production, and ocular surface staining to evaluate damage on the ocular surface. Conflicting results among these tests have often been observed and agreements have been proven poor. The tear system is highly dynamic and may be influenced by many internal and external factors.

Some issues in these clinical tests, such as the use of dye and reflex production of tears, may contribute to poor specificity and sensitivity. The use of fluorescein might cause reflex tearing, resulting in great variation. Local anesthesia might alter the tear system, including tear secretion and drainage, possibly resulting in conflicting results in the Schirmer’s test.

Decreased tear meniscus has been previously demonstrated in dry eye patients. Tear meniscus measurements made by slit-lamp and Tearscope (Keeler Inc, Windsor, UK), especially for the lower tear meniscus, have been used to evaluate the tear system. OCT is a noninvasive and noncontact imaging modality that has been used for imaging the tear film and tear meniscus. Using a custom-built, real-time OCT instrument with a wide scan width, Wang and associates were the first to image both upper and lower tear menisci simultaneously and to investigate tear dynamics during the blink cycle. OCT has also been used to quantify tear dynamics and tear meniscus for the diagnosis of dry eye and for the evaluation of tear dynamics after instillation of artificial tears or occlusion of the punctum. With the use of high-resolution OCT, we have shown that tear meniscus curvature and height show good diagnostic accuracy, with more than 87% for both specificity and sensitivity in the diagnosis of dry eye. Due to its noninvasive and noncontact nature, OCT appears to be very suitable for evaluating tear meniscus volume without any stimulus for possible reflexive tearing.

In the present study, we utilized a high-resolution OCT for the first time to evaluate changes in the tear meniscus following the use of a topical cyclosporine in dry eye patients. A measurable increase of tear meniscus volume was found after 2 months of Restasis treatment. This is consistent with prior studies, which have demonstrated an increase of 10 mm or more in Schirmer’s test in 15% of patients versus 5% in control patients. Treatment with topical cyclosporine has been found to reduce the expression of proinflammatory cytokines, cell surface markers of T lymphocytes, and apoptotic cells in dry eye patients. Improvement of dry eye symptoms and signs has also been demonstrated.

### Table 1 Upper and lower tear meniscus volumes (mean ± standard deviation) before and after treatment with Restasis®

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>1 month</th>
<th>2 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>LTMV</td>
<td>0.43 ± 0.18</td>
<td>0.62 ± 0.28</td>
<td>0.69 ± 0.37</td>
</tr>
<tr>
<td>UTMV</td>
<td>0.40 ± 0.19</td>
<td>0.59 ± 0.40</td>
<td>0.56 ± 0.26</td>
</tr>
</tbody>
</table>

**Note:** Unit of measurement, microliter (µL).

**Abbreviations:** LTMV, lower tear meniscus volume; UTMV, upper tear meniscus volume.

---

**Discussion**

Many clinical tests have been used to evaluate the tear system and, ultimately, to diagnose dry eye. These tests include tear break-up time for tear stability, Schirmer’s test for tear production, and ocular surface staining to evaluate damage on the ocular surface. Conflicting results among these tests have often been observed and agreements have been proven poor. The tear system is highly dynamic and may be influenced by many internal and external factors.
In the present study, after 1 month of Restasis treatment, the upper tear meniscus volume in the treatment group (0.59 µL at 1 month and 0.56 µL at 2 months) increased to a value similar to normal eyes tested in an earlier study (0.58 µL). With increased tear production, the upper tear meniscus should increase first, before the tears are transferred to the lower tear meniscus. The lower tear meniscus continued to improve at 1 and 2 months; though, at the final visit, the lower tear meniscus volume (0.69 µL) had still not approached that of a normal group (0.81 µL). This suggests that 2 months of treatment alone may not achieve full recovery to a normal level. However, age may be a factor when normal volume of the tear meniscus is considered and additional studies, perhaps of longer duration, with age-matched controls are necessary to fully address whether the treatment can fully restore the tear production to an age-matched normal level.

The tear menisci act as reservoirs; tears newly secreted by the lacrimal gland flow first to the upper tear meniscus and then to the lower tear meniscus via the lid junctions. During blinking, the upper and lower tear menisci are mixed and form a thin tear film on the ocular surface. It has been documented that artificial tears do not lead to sustained increases in tear volume, as blinking returns tear volume.

**Figure 2** Tear menisci before and after 2 months of Restasis® treatment.

**Notes:** The upper (UTM) and lower (LTM) tear menisci were imaged at baseline, 1, and 2 months from both eyes of a dry eye subject. The tear menisci appeared increased at 1 and 2 months, compared to baseline. Bars = 500 µm.

**Abbreviations:** OD, oculus dexter; OS, oculus sinister.

**Figure 3** Upper and lower tear menisci before and after Restasis® treatment in dry eye patients.

**Notes:** Upper (UTMH) and lower (LTMH) tear menisci heights were significantly increased at 1 and 2 months compared with baseline (P < 0.05). Bars represent 95% confidence intervals.
to baseline within a very short period after artificial tear instillation.\textsuperscript{4,8} Wang and associates tracked tear meniscus volumes with four different artificial tears and found that the instilled tear volume in the tear meniscus appeared to decrease to baseline level within 30 minutes.\textsuperscript{8} In the present study, all measurements were taken at least 2 hours after drop instillation to avoid possible effects from instillation of the fluid vehicle of Restasis.

There are some limitations in the present study. Tear volume was estimated using lid length and tear meniscus area at the central lid, as we did in a previous study,\textsuperscript{8} which could have resulted in some measurement error. Significant increases of the tear meniscus after treatment, compared to baseline, were evident, even with the measurement error. Further, blinking rate is a factor of tear dynamics\textsuperscript{25,26} but is difficult to control. Normal blinking was allowed during imaging, and the image was acquired shortly after blinking, which may lower the impact on the tear meniscus of the blinking rate. Further studies will address this issue by controlling the blinking interval during imaging. Finally, this was a pilot study to determine the tear volume after dry eye treatment. In this study, the subjects were not randomly chosen and no control group was used. In addition, this was not a double-blind study. However, the study will still provide useful information, possibly leading to well-designed clinical trials on the efficacy of dry eye treatment.

**Conclusion**

UHR-OCT is capable of monitoring tear meniscus volume after dry eye treatment with Restasis (0.05% cyclosporine). A measurable increase in tear meniscus volume was evident after 2 months of treatment with Restasis in ATD dry eye patients.

**Acknowledgments**

This study was supported by research grants from Allergan Inc, the National Institutes of Health (NIH grant P30 EY014801), and Research to Prevent Blindness (New York, NY). We wish to thank Dr Britt Bromberg of Xenofile Editing (New Orleans, LA), for providing editing services for this manuscript.

**Disclosure**

Jianhua Wang is a recipient of the research grant from Allergan Inc. The authors have no proprietary interest in any materials or methods described within this article.

**References**


